Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Last trade$215.79
Day change-$0.68 (-0.31%)
Day range$214.47 – $217.28
Volume769,140
Market cap$58.96B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$58.96B
Price / earnings
62.66×
Price / book
2.41×
Price / sales
2.83×
EV / sales
3.6×
EV / EBITDA
13.58×
Profitability
Earnings per share
$3.45
Return on assets
1.85%
Return on equity
3.85%
Dividend yield
1.99%
Liquidity and leverage
Debt / equity
0.69×
Current ratio
0.87×
Quick ratio
0.51×
Cash ratio
0.08×
Cash flow
Price / cash flow
18.09×
Price / free cash flow
23.29×
Free cash flow
$2.53B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BDX, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$4.98B
$4.71B
$5.25B
$5.89B
$4.73B
$4.48B
$5.17B
$5.44B
Cost of revenue
$2.67B
$2.56B
$2.84B
$3.09B
$2.49B
$2.62B
$2.93B
$2.95B
Gross profit
$2.32B
$2.15B
$2.41B
$2.8B
$2.24B
$1.86B
$2.24B
$2.49B
Selling, general and administrative
$1.26B
$1.21B
$1.39B
$1.37B
$1.16B
$1.12B
$1.32B
$1.26B
Research and development
$258M
$249M
$306M
$322M
$230M
$232M
$343M
$302M
Total operating expenses
$1.65B
$2.06B
$1.81B
$1.82B
$1.5B
$1.48B
$1.75B
$1.73B
Operating income
$663M
$93M
$601M
$981M
$739M
$384M
$482M
$759M
Interest expense
-$132M
-$149M
-$153M
-$155M
-$152M
-$150M
-$155M
-$155M
Income before taxes
$554M
$39M
$392M
$510M
$569M
$201M
$306M
$514M
Income taxes
$102M
$76M
$11M
$17M
$118M
$43M
$3M
$114M
Net income
$378M
-$311M
$381M
$493M
$574M
$308M
$303M
$400M
Net income attributable to common shareholders
$377M
-$311M
$382M
$493M
$574M
$308M
$303M
$400M
EBITDA
$1.32B
$1.15B
$1.33B
$1.74B
$1.41B
$1B
$1.18B
$1.52B
Basic earnings per share
$1.37
-$1.11
$1.34
$1.72
$2.00
$1.07
$1.05
$1.38
Diluted earnings per share
$1.37
-$1.11
$1.34
$1.71
$2.00
$1.07
$1.04
$1.36
Recent news
Company coverage with links to the original publishers.
Three healthcare dividend stocks—AbbVie, Gilead Sciences, and Becton, Dickinson—have significantly outperformed the S&P 500 in 2026, with gains of 29%, 37%, and 43% respectively. All three are recommended as continued buys due to strong underlying businesses, solid dividend programs (two are Dividend Kings), and favorable long-term growth prospects driven by key product pipelines and market tailwinds.
Boston Scientific (BSX) lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 due to unexpected headwinds in its WATCHMAN and Electrophysiology franchises. WATCHMAN organic sales fell 5.9% amid weakening demand, while Electrophysiology declined 5.3% due to competitive pressure from Pulsed Field Ablation technologies. The company faces additional challenges from delayed product launches, elevated debt levels, and a cybersecurity incident that accelerated competitive share losses. BSX shares have declined 53.5% year-to-date, significantly underperforming peers and the broader market.
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
Following a significant market crash where the Nasdaq dropped 5.5% and $2.3 trillion in market value was wiped out due to tech stock selloffs and AI concerns, three companies recently announced dividend increases: Becton Dickinson ($1.06/share, 8th hike in 5 years), Cencora ($0.66/share, 6th hike in 5 years), and UniFirst ($0.38/share, 6th hike in 5 years). These dividend-paying stocks are highlighted as potential defensive investments for conservative investors seeking steady income during market turbulence.
Becton, Dickinson and Company (BD) delivered better-than-expected Q4 fiscal 2026 results with adjusted EPS up 27.3% and revenues up 5.4%, driven by growth across all four business segments. However, the stock fell 6.4% in pre-market trading due to weak fiscal 2027 guidance projecting only low-single-digit revenue growth and adjusted EPS of $13.10-$13.30. Concerns also include sluggish Connected Care revenue growth and declining Medication Management Solutions sales.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$1.06 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 10, 2026
Pay date
Dec 31, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 9, 2026
$1.05
Sep 30, 2026
recurring
Jun 9, 2026
$1.05
Jun 30, 2026
recurring
Mar 10, 2026
$1.05
Mar 31, 2026
recurring
Dec 8, 2025
$1.05
Dec 31, 2025
recurring
Sep 8, 2025
$1.04
Sep 30, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.